| Therapeutic | Carotuximab |
| Target | ENG/CD105 |
| Heavy Chain | EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRSKASNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTRWRRFFDSWGQGTTLTVSS |
| Light Chain | QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPLTFGAGTKLELK |
| 100% seqID Fv Structure | None |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (Feb '25) | Phase-II |
| Estimated Status (Feb '25) | Discontinued |
| Recorded Developmental Technology | |
| INN Year Proposed | 2015 |
| INN Year Recommended | 2016 |
| Companies Involved | National Cancer Institute (USA), Santen Pharmaceutical, TRACON Pharmaceuticals, University of Alabama at Birmingham, University of Minnesota, Roswell Park Cancer Institute |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Fallopian tube cancer, Ovarian cancer, Peritoneal cancer, Prostate cancer, Haemangiosarcoma, Choriocarcinoma, Glioblastoma, Liver cancer, Renal cell carcinoma, Soft tissue sarcoma, Breast cancer, Non-small cell lung cancer, Acute myeloid leukaemia, Colorectal cancer, Precursor B-cell lymphoblastic leukaemia-lymphoma, Wet age-related macular degeneration |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
